ClinicalTrials.gg
RecruitingNCT07227727EDASCIUpdated Nov 14, 2025

Endothelial Dysfunction After SCI

An observational study in Spinal Cord Injuries and Endothelial Dysfunction, sponsored by Craig Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-14.

Sponsored by Craig Hospital · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Spinal Cord Injuries by Craig Hospital — 6 open to participants now, 7 under way, none of them phase 3. Spinal Cord Injuries · Craig Hospital.

Started
2025
with 3 others
Observational
4 of 21
3 open now
Registered
20th of 21
by date

Among the 21 studies in Spinal Cord Injuries by Craig Hospital, this one is one of 4 that started in 2025, is one of 4 observational ones, and was the 20th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

6 of the 21 studies in Spinal Cord Injuries by Craig Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Spinal Cord Injuries by Craig Hospital, or all of them as a file.
02

Study summary

This study plans to learn how endothelial cells, single cell lining of blood vessels may be dysfunctional after a spinal cord injury. Endothelial dysfunction will be measured by the capacity of blood vessels to vasodilate (increase in size) and alter blood flow is lower in adults with a spinal cord injury in comparison to adults without a spinal cord injury. The mechanisms which may alter this function may be critical in reducing the risk of heart attacks and strokes in people with spinal cord injuries.

Read the detailed description

Vascular endothelial dysfunction is prevalent after spinal cord injury (SCI) which predispose individuals with SCI to accelerated, atherosclerotic cardiovascular disease (ASCVD) and future myocardial infarctions and ischemic strokes. The central objective of this study is to determine whether adults with SCI exhibit impaired endothelial function. Specifically, if endothelium-dependent vasodilation is impaired and if endothelial cell derived microvesicles (EMVs) are elevated and dysfunctional in adults with paraplegia. Endothelium-dependent vasodilation will be assessed by pharmacologically manipulating endothelial vasodilator function in live conscious humans with SCI and determining the role of circulating EMVs as both a systemic biomarker and mediator of endothelial dysfunction.

03

Conditions studied

  • Spinal Cord Injuries
  • Endothelial Dysfunction

Keywords

  • spinal cord injury
  • endothelium-dependent vasodilation
  • extracellular vesicles
  • microvesicles
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Potential participants of this study will all be willing and eligible adults who sustained a spinal cord injury, and adults who have never sustained a spinal cord injury. Participants of all races and ethnic backgrounds will be included in this study. A total up to 40 participants will be enrolled with the goal of 20 in each group to complete the protocol.

Eligibility criteria

SCI Inclusion Criteria

  • Over age 18 years
  • Chronic (>12 months) SCI
  • Motor complete (AIS A/B) SCI
  • Paraplegia (neurological level of injury [NLI] at T2 or below)

Non-injured Inclusion Criteria

  • Over age 18 years

Exclusion Criteria (Both SCI and Non-injured)

  • Overt chronic diseases as assessed by: a) clinically documented medical history; b) physical examination; c) blood pressure and at rest; and d) complete blood chemistries and hematological evaluation.
  • Active infection
  • Recent (\< 3 months) surgery
  • Current smoking history (within past 12 months)
  • Report more than low-risk alcohol consumption
  • History of drug abuse
  • Currently taking cardiovascular (statins, beta-blockers) therapeutics and/or other medications that could influence the outcome measures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Spinal Cord Injury

    Willing and eligible adults over the age of 18 years who sustained a motor complete (AIS A/B) paraplegia (neurological level of injury at T2 or below) spinal cord injury greater than 12 months ago. Participants of all races and ethnic backgrounds will be included in this study.

    Procedure: Intra-arterial Infusion of Vasoactive Agents · Procedure: Intra-arterial Vitamin C Infusion · Procedure: Blood Sampling

  • Control (Non-Spinal Cord Injury)

    Adults greater than 18 years of age who have never sustained a spinal cord injury. Participants of all races and ethnic backgrounds will be included in this study

    Procedure: Intra-arterial Infusion of Vasoactive Agents · Procedure: Intra-arterial Vitamin C Infusion · Procedure: Blood Sampling

Interventions

  • ProcedureIntra-arterial Infusion of Vasoactive Agents

    A catheter is placed in the brachial artery of the non-dominant arm, and small doses of vasoactive drugs \[acetylcholine (Ach), isoproterenol (ISO), sodium nitroprusside (SNP)\] are infused. Forearm blood flow (FBF) is measured using venous occlusion plethysmography. The purpose of this procedure is to assess endothelium-dependent and independent vasodilation by stimulating different vascular pathways. The Ach infusion is to test muscarinic receptor, nitro oxide (NO) dependent, endothelium-dependent vasodilation. ISO infusion is to evaluate β-adrenergic, NO-dependent endothelium-dependent vasodilation. SNP infusion is to assess endothelium-independent vasodilation.

  • ProcedureIntra-arterial Vitamin C Infusion

    Vitamin C, a potent antioxidant, will be infused into the arm and forearm blood flow (FBF) will be re-evaluated to determine whether oxidative stress contributes to endothelial dysfunction.

  • ProcedureBlood Sampling

    Blood will be sampled from the antecubital vein (\~50 mL) for biomarker analysis. This is to assess circulating biochemical and molecular indicators of vascular health and inflammation including levels of endothelial cell derived microvesicles (EMVs)

06

What researchers measure

Primary outcomes

  1. Endothelium-dependent vasodilation

    Total forearm blood flow with be measured by strain gauge venous plethysmography under baseline conditions and under pharmacological manipulation with acetylcholine and isoproterenol at increasing concentrations.

    Time frame: Measured at baseline and immediately after each vasoactive dose for 3-5 minutes.

  2. Endothelium-independent vasodilation

    Total forearm blood flow with be measured by strain gauge venous plethysmography under baseline conditions and under pharmacological manipulation with sodium nitroprusside at increasing concentrations (1, 2, 4ug/ml).

    Time frame: Measured at baseline (without sodium nitroprusside) and immediately after each sodium nitroprusside dose for 3-5 minutes.

  3. Endothelial cell-derived microvesicles concentration

    Endothelial cell-derived microvesicles will be collected from venous blood samples and counted used flow cytometry to determine a circulating concentration.

    Time frame: Baseline

  4. Endothelial cell-derived microvesicles effects of human coronary artery endothelial cells nitric oxide bioavailability

    Endothelial cell-derived microvesicles will be sorted and collected by fluorescence-activated cell sorting (FACS) flow cytometry. The endothelial cell-derived microvesicles will be co-cultured with human coronary artery endothelial cells. Endothelial Nitric Oxide Synthase and phosphorylation sites of interest will be measured by intracellular protein expression quantification of whole cell lysates by capillary electrophoresis immunoassays. Nitric oxide production will be assessed by total nitric oxide and nitrate/nitrite parameter assays.

    Time frame: Baseline

  5. Endothelial cell-derived microvesicles effects of human coronary artery endothelial cells reactive oxygen species and antioxidant capacity

    Endothelial cell-derived microvesicles will be sorted and collected by fluorescence-activated cell sorting (FACS) flow cytometry. The endothelial cell-derived microvesicles will be co-cultured with human coronary artery endothelial cells. Super oxide dismutase and catalase expression will be measured by intracellular protein expression quantification of whole cell lysates by capillary electrophoresis immunoassays. Intracellular oxidative stress will be assessed by ROS-Glo H2O2 assay.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data sharing will be facilitated through active participation in Open Data Commons for SCI (ODC-SCI). ODC-SCI is a cloud-based community-governed repository to store, share, and publish research data on Spinal Cord Injury and is compliant with requirements for FAIR and trustworthy repositories established by NIH.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2025
First posted
Nov 13, 2025
StartActual
Jul 31, 2025
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Nov 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07227727
Lead sponsor
Craig Hospital
Collaborators
University of Colorado, Boulder, Denver Health and Hospital Authority
Responsible party
Andrew Park (Physician Researcher at Craig Hospital, Craig Hospital) — Principal investigator
First posted
Nov 13, 2025
Start date
Jul 31, 2025
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Nov 14, 2025

Study contacts

Genevieve Madera, BS
Contact
Gmadera@craighospital.org
17203454640
Clare Morey, SLP-CCC
Contact
Gquintero@craighospital.org
303.789. 8621
Andrew Park, MD
principal investigator · Craig Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion